Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Non-Current Assets (2022 - 2025)

Historic Non-Current Assets for Envoy Medical (COCH) over the last 4 years, with Q3 2025 value amounting to $2.4 million.

  • Envoy Medical's Non-Current Assets rose 720.92% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.5 million, marking a year-over-year increase of 7111.55%. This contributed to the annual value of $2.6 million for FY2024, which is 22417.18% up from last year.
  • As of Q3 2025, Envoy Medical's Non-Current Assets stood at $2.4 million, which was up 720.92% from $2.4 million recorded in Q2 2025.
  • In the past 5 years, Envoy Medical's Non-Current Assets registered a high of $427.2 million during Q3 2022, and its lowest value of $750000.0 during Q1 2024.
  • Moreover, its 4-year median value for Non-Current Assets was $2.4 million (2025), whereas its average is $92.4 million.
  • As far as peak fluctuations go, Envoy Medical's Non-Current Assets tumbled by 9979.59% in 2023, and later soared by 22417.18% in 2024.
  • Envoy Medical's Non-Current Assets (Quarter) stood at $908000.0 in 2022, then decreased by 10.24% to $815000.0 in 2023, then skyrocketed by 224.17% to $2.6 million in 2024, then decreased by 8.25% to $2.4 million in 2025.
  • Its Non-Current Assets was $2.4 million in Q3 2025, compared to $2.4 million in Q2 2025 and $2.1 million in Q1 2025.